Greenwich LifeSciences, Inc. (GLSI) is a clinical-stage biopharmaceutical company based in Stafford, Texas, developing GLSI-100, an immunotherapy built on the GP2 peptide designed to prevent recurrence in HER2-positive breast cancer patients. The company has no product revenue and its entire valuation rests on FLAMINGO-01, a Phase III trial carrying FDA Fast Track designation.
The stock was trading at $18.72 in the final hour of Tuesday's session, a gain of 36.05% from the prior close of $13.76. Shares opened sharply higher at $16.06, reached $19.28 intraday and traded as low as $15.73, with roughly half a million shares changing hands against a recent daily average near 67,000.
The decisive trigger arrived before the opening bell. Greenwich said two abstracts, along with two corresponding poster presentations, had been accepted for publication at the 2026 San Antonio Breast Cancer Symposium, scheduled for December 8–11. Both posters, authored by the FLAMINGO-01 Steering Committee, will be presented on December 9 in the sessions reserved for ongoing clinical trials and late-breaking abstracts.
That placement matters for a micro-cap with a binary clinical story. Late-breaking slots are typically reserved for data perceived as practice-relevant, and the market read the acceptance as a signal that the steering committee has meaningful recurrence and immune-response findings to share. The company also refreshed corporate slides, trial-design materials, a fireside chat and an analyst commentary posting alongside the release. Notably, the announcement did not disclose abstract titles or new trial data, which limits how much of the move can be attributed to the disclosure itself.
Tuesday's advance also carried the shape of a relief rebound. On Monday the stock fell 7.90% after the company reported a third-quarter net loss of $5.81 million, or $0.40 per share, versus $3.71 million a year earlier and a consensus estimate near a $0.34 loss. Cash stood at $5.9 million as of September 30, and the filing reiterated that operations depend on raising additional capital.
That combination left the shares at their lowest close since early November, down more than 27% from the October 29 level of $19.00. Buyers returning to a beaten-down, event-driven name with a scheduled December catalyst is a common pattern in clinical-stage biotech, and it fits the timing of Tuesday's reversal.
With about 14.7 million shares outstanding and a float historically a fraction of that, Greenwich carries a small capitalization of roughly $275 million at current prices. Management and directors hold a large majority of the equity, so relatively modest buying pressure can move the quote disproportionately. The 8.2-fold expansion in share turnover relative to the average is consistent with a thin order book being swept rather than with broad institutional accumulation.
The move was entirely company-specific. The SPDR S&P Biotech ETF (XBI) slipped about 0.5% and the iShares Biotechnology ETF was down roughly 0.6%, while the Nasdaq-100 proxy fell more than 1% and small-caps dropped about 1.4% as risk appetite weakened. Nothing in the sector tape explains a 36% gain.
Technically, the stock reclaimed the $15 and $17 zones that had capped it during the November slide and pushed back above its early-October range, though it remains roughly 45% below its 52-week high of $34.10 and well under the $25.36 average price at which shares were sold through its at-the-market program in the first half of the year.
The score runs from 0, meaning no meaningful news and an ordinary move for the stock, to 100, meaning transformative news and an extreme, rare price move. Greenwich LifeSciences earns 63 out of 100.
The verified news was moderate at best: a conference acceptance with no new data, material for visibility but not a fundamental re-rating. The price behavior was the dominant factor. At 36.05%, Tuesday's swing was 8.2 times the stock's average absolute daily move of 4.4% over the prior 69 sessions, and no session in that stretch came close — the largest was a 17.66% gain. Moderate news combined with exceptional price behavior produces the mid-60s score.
The December 9 posters are the next scheduled information event, and investors will look for recurrence rates, immune-response measurements and any detail on the open-label non-HLA-A*02 cohort. Beyond that, the FLAMINGO-01 interim analysis for superiority and futility triggers once 14 recurrence events accrue in the blinded arms, a timing the company does not control. Enrollment expansion toward 150–200 global sites and European regulatory filings are additional milestones.
Analyst coverage remains sparse, and the fourth-quarter report is expected in the new year. The key risks are unchanged: a going-concern disclosure, cash of under $6 million, dilution through further at-the-market sales, and the possibility that conference data disappoint. A trial that has not reported randomized results leaves ample room for volatility in both directions.
Tickeron offers hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions appear in its curated Trending AI Robots section. Bots differ by strategy, timeframe, performance metrics and the symbols they trade, so the lineup shifts as market conditions evolve. Exploring the page is a practical way to see which automated approaches are working right now.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Be on the lookout for a price bounce soon.
Following a +12.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where GLSI advanced for three days, in 212 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GLSI as a result. In 79 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for GLSI turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 35 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
GLSI moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for GLSI crossed bearishly below the 50-day moving average on November 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 18 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GLSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
GLSI broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GLSI entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 57 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. GLSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: GLSI's P/B Ratio (71.438) is slightly higher than the industry average of (3.586). P/E Ratio (-9.541) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GLSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology